Santhera Appoints Marc Clausse as Chief Commercial Officer to Lead Next Phase of Growth
MWN-AI** Summary
Santhera Pharmaceuticals has announced the appointment of Marc Clausse as its new Chief Commercial Officer (CCO), effective June 1, 2026. Clausse succeeds Geert Jan van Daal, who will retire after a notable 11-year tenure at Santhera but will assist in the transition during the coming months. With over 25 years of experience in the life sciences sector, Clausse is recognized for his extensive expertise in specialty pharmaceuticals, oncology, and rare diseases. His background includes significant roles at Mirum Pharmaceuticals and GlaxoSmithKline, where he demonstrated a strong ability to drive commercial growth and establish successful market access strategies.
In his most recent role as VP of International Strategy & Operations at Mirum, Clausse played a pivotal role in building regional commercial infrastructure and securing distributor partnerships across Europe, consistently exceeding revenue targets. His prior experience includes leading the oncology portfolio at GSK, where he achieved a market-leading position for the ovarian cancer treatment.
Outgoing CCO Geert Jan van Daal has provided critical leadership during his time, including overseeing the European launch of AGAMREE® (vamorolone), which has significantly expanded patient access. Dario Eklund, Santhera's CEO, expressed gratitude to van Daal for his contributions and welcomed Clausse’s leadership, emphasizing the company’s commitment to growth and patient-focused initiatives.
Clausse acknowledged the importance of AGAMREE for patients with Duchenne muscular dystrophy (DMD) and expressed eagerness to drive global access and enhance Santhera’s commercial capabilities. Santhera, based in Switzerland, specializes in developing innovative treatments for rare neuromuscular diseases, with AGAMREE being a key product approved across multiple regions.
MWN-AI** Analysis
Santhera Pharmaceuticals' recent appointment of Marc Clausse as Chief Commercial Officer marks a pivotal moment for the company, poised to significantly impact its trajectory in the market. With over 25 years of global experience, particularly in specialties such as oncology and rare diseases, Clausse's proven track record in driving commercial growth aligns seamlessly with Santhera's ambition to scale its operations and enhance its market presence, especially following the successful launch of AGAMREE® (vamorolone).
Investors should view this transition positively as Santhera enters a critical phase of expansion. Clausse's experience with Mirum Pharmaceuticals in building commercial infrastructure and establishing distributor partnerships underscores his capability to navigate complex market dynamics, especially in Europe, where market access and pricing strategies are pivotal. This background suggests that under his leadership, Santhera could improve AGAMREE's accessibility, enhancing its market potential.
Moreover, the company's strategic positioning in niche areas of the pharmaceutical market—focused on rare neuromuscular diseases—could prove advantageous, particularly given the high unmet medical need. The international licensing agreements for AGAMREE strengthen Santhera's revenue diversification, reducing reliance on any single market and paving the way for future profitability.
Investors should closely monitor Clausse’s impact on Santhera’s operational execution and market strategy as the company seeks to expand its global footprint and create sustained value. As AGAMREE gains traction, its performance will be crucial for overall company growth.
In conclusion, Santhera presents a compelling opportunity for investors looking to capitalize on the growth potential within specialty pharmaceuticals, especially with Clausse at the helm to drive this promising agenda. A watchful stance is advisable as developments unfold over the coming quarters.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Pratteln, Switzerland, March 10, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces the appointment of Marc Clausse as Chief Commercial Officer (CCO), effective June 1, 2026. He succeeds Geert Jan van Daal, who will retire after 11 years with Santhera and will remain available to support an orderly transition over the coming months.
Proven commercial leadership to drive Santhera’s next phase of growth
Marc Clausse brings over 25 years of international experience in the life sciences industry, with deep expertise across specialty, oncology and rare diseases. He has a strong track record of building high-performing teams, leading complex international organizations, and delivering sustained commercial growth in both emerging biotech and established specialty pharmaceutical companies. His experience spans the full commercial value chain, with a particular strength in European market access, pricing and reimbursement, and strategic partner management.
Most recently, Marc served as VP of International Strategy & Operations and UK General Manager at Mirum Pharmaceuticals, where he defined and executed the company’s international strategy. In this role, he co-led the buildout of regional commercial infrastructure, served as a key decision-maker in market access negotiations, and established distributor partnerships across Europe and other international markets. Under his leadership, the organization consistently outperformed revenue targets across product launches.
Previously, Marc was VP, Oncology Head UK & Ireland at GSK, where he led the ovarian cancer portfolio to a market-leading position and oversaw the integration of Tesaro UK following its acquisition in 2018. Earlier, as General Manager UK & Ireland at Tesaro, he led all commercial, medical and market access functions, establishing pricing and reimbursement pathways and positioning the organization for sustained growth.
Orderly transition to sustain commercial execution and growth
Geert Jan joined Santhera in 2015 as General Manager for France and Benelux and subsequently assumed broader leadership responsibilities across Europe, including Iberia, the UK/Ireland and Western Europe. He was appointed Chief Commercial Officer in January 2024 and led the European launch of AGAMREE® (vamorolone), significantly expanding patient access across and beyond the Company’s core markets.
“On behalf of the Board and Executive Committee, I would like to thank Geert Jan for his significant contributions to Santhera, including the successful launch of AGAMREE in Europe,” said Dario Eklund, Chief Executive Officer of Santhera. “I am also delighted to welcome Marc as we enter our next phase of growth. His leadership will be instrumental as we scale our commercial platform, expand our international reach and evolve our portfolio to create long-term value for patients and shareholders.”
Marc Clausse, newly appointed CCO, added: “AGAMREE represents a meaningful advancement for patients with DMD, and Santhera is well positioned for its next phase of growth. I look forward to working with Dario and the team to accelerate global access to AGAMREE and strengthen the Company’s commercial platform.”
Geert Jan van Daal, outgoing CCO, commented: “It has been a privilege to be part of Santhera’s journey and to contribute to bringing important new treatments to patients with high unmet medical needs. I look forward to supporting the team during the transition.”
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular diseases with high unmet medical need. The Company has an exclusive license from ReveraGen for all indications worldwide to AGAMREE® (vamorolone), a dissociative steroid with novel mode of action, which was investigated in a pivotal study in patients with Duchenne muscular dystrophy (DMD) as an alternative to standard corticosteroids. AGAMREE for the treatment of DMD is approved in the U.S. by the Food and Drug Administration (FDA), in the EU by the European Commission (EC), in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA), in Switzerland by Swissmedic, in China by the National Medical Products Administration (NMPA), in Hong Kong by the Department of Health (DoH) and in Canada by Health Canada. Santhera has out-licensed the rights to AGAMREE as follows: to Catalyst Pharmaceuticals for North America; to Sperogenix Therapeutics for China and certain countries in Southeast Asia; and to Nxera Pharma for Japan, South Korea, Australia, and New Zealand. For further information, please visit www.santhera.com.
AGAMREE® is a trademark of Santhera Pharmaceuticals.
For further information, please contact:
Santhera
Catherine Isted, Chief Financial Officer
IR@santhera.com
ICR Healthcare:
Santhera@icrhealthcare.com
Stifel
+44 (0)20 7710 7600
Brough Ransom, Charles Hoare, Fred Walsh
Octavian
+41 (0)44 520 1588
Serge Monnerat, Marius Zuberbuehler
Disclaimer / Forward-looking Statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
# # #
Attachment
FAQ**
How will Marc Clausse's appointment as CCO influence the commercial strategies of Santhera Pharms Hldgs Ltd SPHDF, particularly in the context of AGAMREE's market access and expansion?
What are the expected implications for Santhera Pharms Hldgs Ltd SPHDF's revenue growth following the transition period after Geert Jan van Daal's retirement?
How does Santhera Pharms Hldgs Ltd SPHDF plan to leverage Marc Clausse's experience to enhance partnerships and market access across Europe for AGAMREE?
What challenges does Santhera Pharms Hldgs Ltd SPHDF anticipate in achieving sustained commercial growth during this leadership transition, and how is it preparing to address them?
**MWN-AI FAQ is based on asking OpenAI questions about Santhera Pharms Hldgs Ltd (OTC: SPHDF).
NASDAQ: SPHDF
SPHDF Trading
0.0% G/L:
$19.95 Last:
800 Volume:
$19.95 Open:
